Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Fidelio Capital on its acquisition of VetFamily
Mandate

Vinge advises Fidelio Capital on its acquisition of VetFamily

February 20, 2019 M&A

Vinge has advised Fidelio Capital on its acquisition of VetFamily, an alliance for independent veterinary clinics for, inter alia, clinic cooperation and procurement with operations in Sweden, Norway, Denmark, Germany and the Netherlands.

Vinge’s team consisted of, among others, Jonas Bergström, Manne Bergström, Samra Baytar and Fredric Reissmüller (M&A/Corporate), Eva Fredriksson, Mika Jordan, Hedvig Ekdahl and Fredrika Hjelmberg (Commercial Agreements), Karin Virding (Intellectual Property), Johan Karlsson and Sebastian Örndahl (EU, Competition & Regulatory), Sara Strandberg and Sarah Berger (Employment) and Viktoria Owetz (VDR).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024